Advertisement
Canada markets close in 43 minutes
  • S&P/TSX

    22,209.96
    +102.88 (+0.47%)
     
  • S&P 500

    5,261.16
    +12.67 (+0.24%)
     
  • DOW

    39,836.02
    +75.94 (+0.19%)
     
  • CAD/USD

    0.7383
    +0.0010 (+0.14%)
     
  • CRUDE OIL

    83.08
    +1.73 (+2.13%)
     
  • Bitcoin CAD

    95,818.95
    +2,496.38 (+2.68%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,241.70
    +29.00 (+1.31%)
     
  • RUSSELL 2000

    2,125.02
    +10.67 (+0.50%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • NASDAQ

    16,401.38
    +1.86 (+0.01%)
     
  • VOLATILITY

    12.90
    +0.12 (+0.94%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • CAD/EUR

    0.6841
    +0.0036 (+0.53%)
     

GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit

Atlanta, Georgia--(Newsfile Corp. - May 11, 2021) - GeoVax Labs, Inc. (NASDAQ: GOVX) today announced that David Dodd, Chairman & CEO will be attending the Q2 Virtual Investor Summit.

 Event

 Q2 Investor Summit

 Date

 May 17-18th, 2021

 Presentation

 May 18th at 8:45 AM ET

 Location

 https://zoom.us/webinar/register/WN_wIcZo2BAR_q1ALp6NyazfA

 

About GeoVax Labs, Inc.

GeoVax is a clinical-stage company developing vaccines against infectious diseases and cancer. GeoVax’s current development programs are focused on preventive vaccines against COVID-19, Zika Virus, hemorrhagic fever viruses (Ebola, Lassa, Marburg and Sudan), HIV and malaria, as well as therapeutic vaccines against multiple cancers. Through the Company’s novel Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within the person receiving the vaccine. The production of VLPs in vivo mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.

ADVERTISEMENT

For further information:

GeoVax Labs, Inc.
Investor Relations
678-384-7220
investor@geovax.com

About the Investor Summit

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q2 Investor Summit will take place virtually, featuring 80+ companies and over 300 institutional and retail investors.

To request complimentary investor registration: please visit our website at www.investorsummitgroup.com

Contact:

Sasha Murray at sasha@investorsummitgroup.com